The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2025 | Investigating the heterogeneity in GPRC5D expression between patients with myeloma
In this video, Harsh Parmar, MD, Hackensack University Medical Center, Hackensack, NJ, discusses the heterogeneity in GPRC5D expression observed in a cohort of 280 patients with multiple myeloma (MM). Dr Parmar highlights that 3% of patients did not express the GPRC5D receptor, although he emphasizes that further studies are needed to determine whether GPRC5D expression levels impact treatment efficacy. This interview took place at the 2025 American Society of Clinical Oncology (ASCO) meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So venetoclax has an important role for treatment of patients with myeloma, particularly the subgroup of patients who have translocation t(11;14). We know that about 1 in 4 patients, or 25% of patients, have this cytogenetic change. And historically speaking, several trials have evaluated the efficacy of venetoclax, including the BELLINI trial. So we analyzed 79 patients at our institute who received venetoclax who had translocation t(11;14), and some of those patients did not...
So venetoclax has an important role for treatment of patients with myeloma, particularly the subgroup of patients who have translocation t(11;14). We know that about 1 in 4 patients, or 25% of patients, have this cytogenetic change. And historically speaking, several trials have evaluated the efficacy of venetoclax, including the BELLINI trial. So we analyzed 79 patients at our institute who received venetoclax who had translocation t(11;14), and some of those patients did not. And obviously, as expected, patients who had t(11;14) translocation had a higher response rate compared to those who did not, and we also found that the median progression-free survival for these patients who had t(11;14) was significantly higher, about 7.8 months, compared to those who did not, where the median PFS was 2.8 months, so clearly you can see the difference in outcomes of these patients. So it’s important to look for this translocation as it drives your treatment strategy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
